Helicobacter pylori Efflux Pumps: A Double-Edged Sword in Antibiotic Resistance and Biofilm Formation
- PMID: 39596287
- PMCID: PMC11594842
- DOI: 10.3390/ijms252212222
Helicobacter pylori Efflux Pumps: A Double-Edged Sword in Antibiotic Resistance and Biofilm Formation
Abstract
Helicobacter pylori is a major pathogen associated with various gastric diseases. Despite decades of research, the treatment of H. pylori remains challenging. One of the primary mechanisms contributing to failures of therapies targeting this bacterium is genetic mutations in drug target sites, although the growing body of scientific data highlights that efflux pumps may also take part in this process. Efflux pumps are proteinaceous transporters actively expelling antimicrobial agents from the interior of the targeted cells and reducing the intracellular concentration of these compounds. Considering that efflux pumps contribute to both antimicrobial resistance and biofilm formation, an in-depth understanding of their properties may constitute a cornerstone in the development of novel therapeutics against H. pylori. In line with this, the aim of the current review is to describe the multitude of efflux pumps produced by H. pylori and present the data describing the involvement of these proteins in tolerance and/or resistance to various classes of antimicrobial substances.
Keywords: Helicobacter pylori; antibiotic resistance; antibiotic tolerance; biofilm; efflux pumps; efflux systems; transporters.
Conflict of interest statement
The author declares no conflicts of interest.
Figures


Similar articles
-
Transporters HP0939, HP0497, and HP0471 participate in intrinsic multidrug resistance and biofilm formation in Helicobacter pylori by enhancing drug efflux.Helicobacter. 2020 Aug;25(4):e12715. doi: 10.1111/hel.12715. Epub 2020 Jun 16. Helicobacter. 2020. PMID: 32548895
-
Bifunctional Enzyme SpoT Is Involved in Biofilm Formation of Helicobacter pylori with Multidrug Resistance by Upregulating Efflux Pump Hp1174 (gluP).Antimicrob Agents Chemother. 2018 Oct 24;62(11):e00957-18. doi: 10.1128/AAC.00957-18. Print 2018 Nov. Antimicrob Agents Chemother. 2018. PMID: 30181372 Free PMC article.
-
Contribution of efflux pumps to clarithromycin resistance in Helicobacter pylori.J Gastroenterol Hepatol. 2010 May;25 Suppl 1:S75-9. doi: 10.1111/j.1440-1746.2009.06220.x. J Gastroenterol Hepatol. 2010. PMID: 20586871
-
Nanomaterials: A Prospective Strategy for Biofilm-Forming Helicobacter pylori Treatment.Int J Nanomedicine. 2025 Apr 23;20:5209-5229. doi: 10.2147/IJN.S512066. eCollection 2025. Int J Nanomedicine. 2025. PMID: 40292401 Free PMC article. Review.
-
Helicobacter pylori Biofilm Formation and Its Potential Role in Pathogenesis.Microbiol Mol Biol Rev. 2018 May 9;82(2):e00001-18. doi: 10.1128/MMBR.00001-18. Print 2018 Jun. Microbiol Mol Biol Rev. 2018. PMID: 29743338 Free PMC article. Review.
Cited by
-
Towards Effective Helicobacter pylori Eradication: Emerging Therapies in the Wake of Antibiotic Resistance.Int J Mol Sci. 2025 Jun 24;26(13):6064. doi: 10.3390/ijms26136064. Int J Mol Sci. 2025. PMID: 40649842 Free PMC article. Review.
-
Challenges and Prospects for Eradication of Helicobacter pylori: Targeting Virulence Factors, Metabolism, and Vaccine Innovation.Pathogens. 2025 Jun 21;14(7):619. doi: 10.3390/pathogens14070619. Pathogens. 2025. PMID: 40732667 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical